TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HBM Holdings Ltd. ( (HK:2142) ) has shared an update.
HBM Holdings Ltd. announced that it will present Phase II clinical data for its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, at the ESMO Congress 2025. This presentation will highlight the efficacy and safety of the treatment for microsatellite stable metastatic colorectal cancer, potentially enhancing the company’s position in the oncology market.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative antibody therapies. The company specializes in fully human heavy-chain-only antibodies, with a market focus on treating various solid tumors using advanced therapeutic platforms.
Average Trading Volume: 10,054,526
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.03B
For an in-depth examination of 2142 stock, go to TipRanks’ Overview page.